Earkart

- There is no explicit mention of any current or planned new fundraising through debt or equity during the call. - Mr. Rohit Misra confirms that sufficient funds are already available following the recent IPO to support the planned expansion, including the installation of devices in clinics. - The company has made provisions to ensure the model becomes self-sustaining by the time of 350 installations. - No mention of additional debt or equity fundraising plans was discussed for future financing. - The focus is on efficient cash use and organic growth, leveraging the existing IPO proceeds for capex and expansion.

- The company has planned installation of around 500 to 550 clinics by the end of FY 2027. - The installation cost per device is approximately ₹2.7 lakh per clinic. - Recent IPO proceeds include unutilized funds sufficient to cover the capex for clinic installations. - By the time 350 installations are achieved, the business model is expected to become self-sustaining. - Expansion involves hiring more employees and setting up new infrastructure to support growth. - Investments are also being made in improving the OMNI Audiometer for better efficiency and availability. - Strategic expansion planned geographically from North India towards West, South, and eventually East India. - Efforts include partnerships with financial institutions (e.g., zero pay NBFC) for interest-free EMI offerings to customers. - Focus on reducing customer acquisition costs by positioning products within ENT practices. Overall, a clear strategy of measured capital expenditure aligned with clinic expansion and technological improvements is in place.

- Earkart aims to reach approximately ₹300 crore turnover in 5 years (by 2030). - Targeting 500 to 550 clinic installations by FY 2027, with installation cost per device around ₹2.7 lakh per clinic. - Expecting a compound annual growth rate (CAGR) of about 25% this year and aiming to sustain similar growth next year. - Private sector revenue share expected to grow to about 70% within 5 years, with government orders range-bound around 20-30%. - Revenue from clinics expected to rise significantly, e.g., from 110 clinics generating roughly ₹10-11 crore at full capacity. - Focus on expanding geographical presence across India, moving from North to West, South, and eventually East. - Anticipate operational cost enhancements with increased hiring and infrastructure to support expansion; margins expected between 20-30% EBITDA. - Private market margins up to 40-45% gross margin projected with increasing private sector focus.

- Earkart aims to become a ₹300 crore company within 5 years (by 2030). - Target to scale up to 500-550 clinics by FY27, with ~₹70,000 installation cost per clinic, funded by IPO proceeds. - EBITDA margins expected between 20-30%, aiming for 23% EBITDA margin this year as expansion costs stabilize. - Gross margins around 40-45% on private sales; government segment margins at 29-32%. - Private sector revenue share expected to increase to ~70% by 2028, with government orders range-bound at 20-30%. - Long-term growth driven by expansion beyond North India to West and South, then East regions. - Operating efficiency expected to rise to 70-80% in 12-19 months, improving margins further. - EPS growth implied via scaling revenue and maintaining healthy margins, with profitability improving as expansions mature.

- Earkart has already secured government orders worth approximately ₹9 crores in the current fiscal year (Page 8, 7th excerpt). - Four government tenders, usually opening before September, were deferred but two have already opened, with 2-3 more expected to open in the second half of the fiscal year (Page 8). - The second half of the year is expected to see a significant scale-up in order inflows due to these tender openings (Page 8). - Private sector orders have grown by over 25% compared to last year, supporting overall revenue despite deferred government orders (Page 8). - The company aims for a 25% compound annual growth rate (CAGR) this year, driven by both government and private orders (Page 8). - No explicit total value of the full order book or pending orders beyond these notes was mentioned in the transcript.